JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure

NCT07798921 | Not Yet Recruiting Phase 1

• 1 other identifier: 4-2026-0527
• Study Type: interventional
• Target: 36
• Locations: 0 countries
• Sites: N/A

Brief Summary

This Phase 1 study will evaluate the safety, maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity of JIN-A02 in combination with amivantamab in participants with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor. The study includes a dose-escalation phase and a dose-expansion phase. During dose escalation, participants will receive oral JIN-A02 once daily at planned dose levels of 120 mg, 160 mg, or 200 mg in combination with weight-based intravenous amivantamab. Dose escalation will follow a Bayesian optimal interval design, and dose-limiting toxicities during the first 28-day treatment cycle will be used to determine the maximum tolerated dose and recommended Phase 2 dose. After the recommended Phase 2 dose is determined, additional participants will be enrolled in the dose-expansion phase to further evaluate safety and preliminary antitumor activity. Efficacy assessments will include objective response rate and progression-free survival according to RECIST version 1.1. Exploratory analyses may evaluate changes in EGFR mutations and resistance-associated genomic alterations using circulating tumor DNA collected before and during treatment and at the end of treatment.

Conditions

Carcinoma; Non-Small-Cell Lung

Outcome Measures

Primary Outcomes (3)

• Incidence of Dose-Limiting Toxicities

  The incidence of dose-limiting toxicities will be evaluated during the first 28-day treatment cycle. Dose-limiting toxicities will be defined and graded according to the criteria specified in the protocol.

  During Cycle 1, up to 28 days after the first dose

• Maximum Tolerated Dose of JIN-A02 in Combination With Amivantamab

  The maximum tolerated dose will be determined based on dose-limiting toxicities observed during Cycle 1 and dose-escalation decisions made according to the Bayesian optimal interval design.

  Through completion of the dose-escalation phase, approximately 8 months

• Recommended Phase 2 Dose of JIN-A02 in Combination With Amivantamab

  The recommended Phase 2 dose will be determined based on the totality of available safety, tolerability, pharmacokinetic, and preliminary antitumor activity data from the dose-escalation phase.

  Through completion of the dose-escalation phase, approximately 8 months

Secondary Outcomes (3)

• Objective Response Rate According to RECIST Version 1.1

  From baseline until documented disease progression, up to approximately 2 years

• Progression-Free Survival According to RECIST Version 1.1

  From the first dose until documented disease progression or death from any cause, whichever occurs first, up to approximately 2 years

• Incidence of Treatment-Emergent Adverse Events

  From the first dose through 30 days after the last dose

Study Arms (1)

JIN-A02 Plus Amivantamab

EXPERIMENTAL

Participants will receive JIN-A02 orally once daily in combination with intravenous amivantamab in 28-day treatment cycles during the dose-escalation and dose-expansion phases.

Drug: JIN-A02 in Combination with Amivantamab

Interventions

JIN-A02 in Combination with Amivantamab DRUG

Participants will receive oral JIN-A02 once daily in continuous 28-day treatment cycles in combination with intravenous amivantamab. During dose escalation, the planned JIN-A02 dose levels are 120 mg, 160 mg, and 200 mg once daily. Amivantamab will be administered at 1,050 mg for participants with a baseline body weight of less than 80 kg or 1,400 mg for participants weighing 80 kg or more. The first amivantamab dose will be split between Cycle 1 Days 1 and 2, followed by administration on Days 8, 15, and 22 of Cycle 1 and every 2 weeks from Cycle 2 onward. On combination-treatment days, JIN-A02 will be administered within approximately 15 minutes before amivantamab.

JIN-A02 Plus Amivantamab

Eligibility Criteria

• Age: 19 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 19 years or older.
• Subjects with advanced and/or metastatic NSCLC harboring an activating EGFR mutation (Ex19del or L858R), as confirmed by testing of tissue or blood samples, whose disease has progressed following treatment with a third-generation EGFR-TKI, such as osimertinib or lazertinib. Subjects who received platinum-based chemotherapy after EGFR-TKI treatment may have received no more than one such regimen.
• Subjects with at least one measurable lesion according to RECIST v1.1.
• Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

You may not qualify if:

• Subjects with NSCLC histologically diagnosed as having a mixed squamous cell component or with histologic transformation, including transformation from NSCLC to small cell lung cancer (SCLC) or the presence of epithelial-to-mesenchymal transition.
• Subjects with uncontrolled symptomatic spinal cord compression or central nervous system (CNS) metastases; subjects requiring an increase in corticosteroid dose within 28 days before study initiation for the treatment of CNS disease; subjects requiring local treatment for CNS disease; or subjects with leptomeningeal disease. However, subjects whose condition remains stable or who are systemically asymptomatic at least 2 weeks after gamma knife treatment or at least 4 weeks after whole-brain irradiation may be eligible to participate in the study.
• Subjects who have received any of the following treatments:
• EGFR-TKI therapy or systemic anticancer therapy within 14 days or 5 half-lives, whichever is longer, before the first dose of the investigational product, or any prior treatment with a fourth-generation EGFR-TKI.
• Limited-field radiotherapy within 7 days or extended-field thoracic radiotherapy within 14 days before the first dose of the investigational product.
• Immunotherapy or other antibody-based therapy within 28 days before the first dose of the investigational product.
• Major surgery, other than procedures such as central venous catheter placement, within 28 days before the first dose of the investigational product, or subjects who, in the investigator's judgment, have not recovered from surgery-related adverse effects.
• \*Major surgery is defined as surgery involving the abdominal, pelvic, cranial, thoracic, or localized tissues that, considering the surgical site, the subject's condition, the complexity of the procedure, or the duration of surgery, may pose a risk to organ or tissue function or to resuscitation. Major surgery generally requires general anesthesia, hospitalization of varying duration, often approximately 1 week, and may be performed by a surgical specialist.
• Subjects with toxicities related to prior anticancer therapy or radiotherapy that have not recovered to CTCAE Grade ≤1 or baseline. Exceptions may be made for toxicities considered clinically acceptable by the investigator, such as alopecia or stable peripheral neuropathy.
• Subjects who have previously received amivantamab.

Sponsors & Collaborators

• Yonsei University: lead

MeSH Terms

Conditions

Carcinoma

Interventions

amivantamab

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2026
• First Posted: September 2, 2026
• Study Start: September 28, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): December 31, 2030
• Last Updated: September 2, 2026

Record last verified: 2026-09